AI-Based Pediatric Medication-Dose Verification: Advancements, Challenges, and Clinical Implications

Abstract

Pediatric medication dosing presents unique challenges due to age-related physiological variability, weight-based calculations, and narrow therapeutic indices. Errors in dose calculation can result in significant morbidity and mortality. Artificial intelligence (AI)-based medication-dose verification systems have emerged as promising tools to enhance patient safety by supporting clinical decision-making, reducing human error, and ensuring guideline-adherent dosing in pediatric populations. This review evaluates the scientific foundations, clinical evidence, and practical implications of AI-driven dose verification in pediatrics, highlighting epidemiological context, mechanistic insights, risk factors, diagnostic considerations, management strategies, recent technological advances, and practice guideline recommendations.

Introduction

Pediatric pharmacotherapy is inherently complex due to developmental pharmacokinetics, dynamic organ maturation, and the prevalence of off-label drug use. Medication errors, particularly dosing errors, remain a leading cause of adverse drug events in children. Traditional safeguards, such as double-checks and manual dose calculations, are frequently insufficient in high-pressure clinical settings. The integration of AI-based dose verification offers a paradigm shift, leveraging machine learning algorithms, large-scale datasets, and real-time clinical context to support healthcare professionals. This article critically examines the role of AI in pediatric dose verification and its translation to bedside safety and efficacy.

Epidemiology / Disease Burden

Medication errors occur in up to 13% of pediatric prescriptions, with dosing errors accounting for a substantial proportion. Neonates and infants are particularly vulnerable, given their frequent exposure to weight-based dosing and limited physiological reserves. Studies estimate that pediatric inpatients experience medication errors at rates two to three times higher than adults, leading to preventable adverse drug events, prolonged hospital stays, and increased healthcare costs. The World Health Organization recognizes pediatric medication safety as a global priority, emphasizing the need for robust technological interventions to mitigate harm.

Pathophysiology

The pathophysiological basis for pediatric dosing complexity stems from age-dependent changes in body composition, organ function, and drug metabolism. Variability in renal and hepatic maturation affects drug clearance and bioavailability, necessitating individualized dosing strategies. Erroneous dosing—whether underdosing or overdosing—can lead to therapeutic failure or toxicity, such as nephrotoxicity from aminoglycosides or central nervous system depression from opioids. AI-based systems integrate patient-specific factors (age, weight, organ function) with drug-specific parameters to generate accurate dosing recommendations in real time.

Risk Factors

Multiple risk factors contribute to pediatric medication-dosing errors. These include complex calculation requirements, lack of standardized dosing references, communication breakdowns, high workload, and insufficient pediatric pharmacology training. Vulnerable populations, such as critically ill neonates, children with chronic conditions, and those receiving polypharmacy, are at greater risk. AI-driven dose verification platforms address these risks by providing automated, evidence-based checks and facilitating multidisciplinary communication within the healthcare team.

Clinical Features

Dosing errors may present with a spectrum of clinical manifestations, ranging from asymptomatic laboratory abnormalities to life-threatening events such as seizures, cardiovascular instability, or acute organ failure. The insidious presentation and nonspecific symptoms of adverse drug events in children often delay recognition and intervention. AI-based verification systems can act as early-warning mechanisms by cross-referencing patient data, medication orders, and dosing guidelines to flag potential discrepancies before administration.

Diagnosis

Diagnosis of medication dosing errors frequently relies on retrospective chart review, incident reporting, and pharmacovigilance systems. However, these methods are limited by underreporting and time lags. AI-powered tools can provide prospective, point-of-care verification by analyzing prescription data, matching it against patient demographics and clinical context, and identifying high-risk orders in real time. Integration with electronic health records (EHRs) further enhances accuracy and traceability, supporting root-cause analysis and continuous quality improvement.

Treatment & Management

Prevention remains the cornerstone of managing pediatric dosing errors. Traditional approaches include pharmacist review, computerized physician order entry (CPOE) systems, and clinical decision support (CDS). AI-based verification augments these modalities by learning from large datasets, recognizing complex patterns, and adapting to evolving clinical guidelines. In cases where errors occur, prompt identification and corrective action—such as dose adjustment, monitoring for toxicity, and supportive care—are essential. AI tools can facilitate rapid response and guide evidence-based management in collaboration with clinical pharmacists and toxicology specialists.

Recent Advances / Emerging Therapies

The field of AI-based pediatric dose verification has witnessed significant advancements, including the use of natural language processing (NLP) to interpret free-text orders, deep learning algorithms to predict high-risk scenarios, and integration with mobile health applications for bedside decision support. Recent studies demonstrate that AI systems can reduce dosing errors by up to 50% in simulated and real-world environments. Federated learning approaches enable continuous model refinement while preserving patient privacy. Emerging therapies include personalized dosing models based on pharmacogenomics and real-time physiological monitoring, offering the potential for truly individualized pediatric therapeutics.

Guideline Recommendations

Professional societies, including the American Academy of Pediatrics and the Institute for Safe Medication Practices, advocate for the adoption of advanced CDS and AI-based verification systems as part of a comprehensive medication safety strategy. Guidelines emphasize the importance of rigorous validation, transparent algorithm development, and clinician oversight to mitigate risks of automation bias and ensure safe implementation. Ongoing education, interdisciplinary collaboration, and robust post-deployment monitoring are essential components of guideline-concordant practice.

Conclusion

AI-based pediatric medication-dose verification represents a transformative innovation in the pursuit of safer, more effective pharmacotherapy for children. By harnessing the power of big data and machine learning, these systems offer real-time, individualized support to clinicians, significantly reducing the risk of dosing errors and adverse drug events. As technology evolves, continued research, clinician engagement, and adherence to evidence-based guidelines will be critical in maximizing the benefits of AI while ensuring patient safety and ethical standards in pediatric care.